140 related articles for article (PubMed ID: 30973677)
1. Association of GSTP1 and ERCC1 polymorphisms with toxicity in locally advanced head and neck cancer platinum-based chemoradiotherapy treatment.
Duran G; Aguín S; Cruz R; Barros F; Giráldez JM; Bernárdez B; López-López R; Carracedo Á; Lamas MJ
Head Neck; 2019 Aug; 41(8):2704-2715. PubMed ID: 30973677
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh.
Bushra MU; Rivu SF; Sifat AE; Nahid NA; Ahmed MU; Al-Mamun MMA; Apu MNH; Islam MS; Islam MR; Islam MS; Hasnat A
Mol Biol Rep; 2020 Sep; 47(9):7073-7082. PubMed ID: 32880833
[TBL] [Abstract][Full Text] [Related]
3. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
4. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy.
Liblab S; Vusuratana A; Areepium N
Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417
[TBL] [Abstract][Full Text] [Related]
5. Effect of DPYD, MTHFR, ABCB1, XRCC1, ERCC1 and GSTP1 on chemotherapy related toxicity in colorectal carcinoma.
Puerta-García E; Urbano-Pérez D; Carrasco-Campos MI; Pérez-Ramírez C; Segura-Pérez A; Calleja-Hernández ; Cañadas-Garre M
Surg Oncol; 2020 Dec; 35():388-398. PubMed ID: 33035787
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant radiochemotherapy in adenocarcinoma of the esophagus: ERCC1 gene polymorphisms for prediction of response and prognosis.
Metzger R; Warnecke-Eberz U; Alakus H; Kütting F; Brabender J; Vallböhmer D; Grimminger PP; Mönig SP; Drebber U; Hölscher AH; Bollschweiler E
J Gastrointest Surg; 2012 Jan; 16(1):26-34; discussion 34. PubMed ID: 21956434
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of GSTP1 and ERCC1 correlated with response to platinum-based chemotherapy in non-small cell lung cancer.
Lv H; Han T; Shi X; Yao Y; Yao Y; Qiu W; Yue L; Liang J
Med Oncol; 2014 Aug; 31(8):86. PubMed ID: 24958519
[TBL] [Abstract][Full Text] [Related]
8. Candidate apoptotic and DNA repair gene approach confirms involvement of ERCC1, ERCC5, TP53 and MDM2 in radiation-induced toxicity in head and neck cancer.
Borchiellini D; Etienne-Grimaldi MC; Bensadoun RJ; Benezery K; Dassonville O; Poissonnet G; Llorca L; Ebran N; Formento P; Château Y; Thariat J; Milano G
Oral Oncol; 2017 Apr; 67():70-76. PubMed ID: 28351583
[TBL] [Abstract][Full Text] [Related]
9. Relationship between clinical toxicities and ERCC1 rs3212986 and XRCC3 rs861539 polymorphisms in cervical cancer patients.
Soares S; Nogueira A; Coelho A; Assis J; Pereira D; Bravo I; Medeiros R
Int J Biol Markers; 2018 Jan; 33(1):116-123. PubMed ID: 28708208
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of oxaliplatin as adjuvant treatment in colon carcinoma: are single nucleotide polymorphisms in GSTP1, ERCC1, and ERCC2 good predictive markers?
Fariña Sarasqueta A; van Lijnschoten G; Lemmens VE; Rutten HJ; van den Brule AJ
Mol Diagn Ther; 2011 Oct; 15(5):277-83. PubMed ID: 21958378
[TBL] [Abstract][Full Text] [Related]
11. Role of common ERCC1 polymorphisms in cisplatin-resistant epithelial ovarian cancer patients: A study in Chinese cohort.
Bao Y; Yang B; Zhao J; Shen S; Gao J
Int J Immunogenet; 2020 Oct; 47(5):443-453. PubMed ID: 32173978
[TBL] [Abstract][Full Text] [Related]
12. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
[TBL] [Abstract][Full Text] [Related]
13. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy].
Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S
Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563
[TBL] [Abstract][Full Text] [Related]
14. DNA-repair gene polymorphisms predict favorable clinical outcome among patients with advanced squamous cell carcinoma of the head and neck treated with cisplatin-based induction chemotherapy.
Quintela-Fandino M; Hitt R; Medina PP; Gamarra S; Manso L; Cortes-Funes H; Sanchez-Cespedes M
J Clin Oncol; 2006 Sep; 24(26):4333-9. PubMed ID: 16896002
[TBL] [Abstract][Full Text] [Related]
15. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
16. Effects of excision repair cross-complementation group 1 (ERCC1) single nucleotide polymorphisms on the prognosis of non-small cell lung cancer patients.
Takenaka T; Yano T; Kiyohara C; Miura N; Kouso H; Ohba T; Kometani T; Shoji F; Yoshino I; Maehara Y
Lung Cancer; 2010 Jan; 67(1):101-7. PubMed ID: 19361884
[TBL] [Abstract][Full Text] [Related]
17. Association of ERCC1 polymorphisms (rs3212986 and rs11615) with the risk of head and neck carcinomas based on case-control studies.
Ding YW; Gao X; Ye DX; Liu W; Wu L; Sun HY
Clin Transl Oncol; 2015 Sep; 17(9):710-9. PubMed ID: 26022132
[TBL] [Abstract][Full Text] [Related]
18. The roles of excision repair cross-complementation group1 in objective response after cisplatin-based concurrent chemoradiotherapy and survival in head and neck cancers: a systematic review and meta-analysis.
Gao Y; Liu D
Oral Oncol; 2015 Jun; 51(6):570-7. PubMed ID: 25857670
[TBL] [Abstract][Full Text] [Related]
19. ERCC1 C8092A polymorphism predicts fair survival outcome in Japanese patients with pharyngo-laryngeal squamous cell carcinoma.
Hirakawa H; Ikegami T; Azechi S; Agena S; Uezato J; Kinjyo H; Yamashita Y; Tanaka K; Kondo S; Maeda H; Suzuki M; Gahana A
Eur Arch Otorhinolaryngol; 2020 Feb; 277(2):601-610. PubMed ID: 31749055
[TBL] [Abstract][Full Text] [Related]
20. Impact of GSTM1, GSTT1 and GSTP1 genes polymorphisms on clinical toxicities and response to concomitant chemoradiotherapy in cervical cancer.
Abbas M; Kushwaha VS; Srivastava K; Raza ST; Banerjee M
Br J Biomed Sci; 2018 Oct; 75(4):169-174. PubMed ID: 29909733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
